Sanofi has reached an important milestone in multiple myeloma management with the U.S. approval of Sarclisa Escena, a subcutaneous formulation of isatuximab-irfc administered using the CirCLIQ on-body injector. The U.S. Food and Drug Administration granted approval on July 9, 2026, marking the first anticancer therapy cleared for administration through an on-body injector. This development highlights the industry's movement toward treatment approaches that can offer greater convenience while maintaining established therapeutic benefits for patients with multiple myeloma.

Sarclisa Escena Approval Strengthens Multiple Myeloma Treatment Convenience

The Sarclisa Escena approval expands the administration options available for SARCLISA without creating a new therapeutic indication. The approved formulation is intended for several multiple myeloma treatment settings. These include newly diagnosed patients who are not eligible for autologous stem cell transplantation when combined with bortezomib, lenalidomide, and dexamethasone. It is also approved for relapsed or refractory disease alongside pomalidomide and dexamethasone following at least two previous therapies, as well as with carfilzomib and dexamethasone following one to three prior treatment lines.

Sarclisa Escena FDA Approval Supported by Multiple Myeloma Clinical Evidence

The Sarclisa Escena FDA approval was supported by results from the Phase III IRAKLIA study. The trial evaluated patients with relapsed or refractory multiple myeloma and compared subcutaneous administration through an on-body injector with intravenous SARCLISA, both used alongside pomalidomide and dexamethasone. The subcutaneous approach achieved an objective response rate of 71.1%, compared with 70.5% for intravenous administration, satisfying the study's predefined non-inferiority criteria. Treatment-related systemic administration reactions were also considerably less frequent with the subcutaneous formulation.

Sanofi Sarclisa Escena Advances Multiple Myeloma Wearable Administration

The Sanofi Sarclisa Escena approach combines an established anti-CD38 monoclonal antibody with wearable drug-delivery technology. CirCLIQ, which is based on Enable Injections' enFuse platform, is designed to provide hands-free administration while attached to the patient's body. This technology may help reduce the time associated with conventional intravenous infusion and potentially decrease demands on healthcare professionals. Consequently, the development represents an important convergence of oncology therapeutics and innovative delivery systems.

Isatuximab FDA Approval Reinforces Multiple Myeloma Treatment Progress

The isatuximab FDA approval builds upon the established clinical role of isatuximab-irfc as an anti-CD38 therapy for multiple myeloma. Offering an automated administration option can provide clinicians and patients with additional flexibility when selecting treatment delivery methods. The availability of the formulation in other major markets, including the European Union and United Kingdom, further demonstrates the broader development of subcutaneous administration for this therapy.

Sarclisa Subcutaneous Innovation Could Reshape Multiple Myeloma Care

The Sarclisa subcutaneous approach could contribute to the wider transformation of biologic cancer treatment delivery. According to DelveInsight, approximately 70,000 patients globally have received SARCLISA-based regimens. Moving away from lengthy infusion-center procedures toward wearable administration may reduce treatment-related burden and improve convenience. The innovation could also encourage pharmaceutical companies to explore similar technologies for other oncology biologics.

Conclusion

The approval represents a meaningful advancement in multiple myeloma care by pairing an established therapeutic approach with an innovative delivery system. Wearable administration has the potential to make treatment more convenient while supporting greater flexibility for patients and healthcare providers. As oncology increasingly prioritizes patient-centered treatment experiences, innovations that simplify administration could become an increasingly important part of future cancer care.

Latest Reports by DelveInsight:

familial mediterranean fever market | food allergy market | functional electrical stimulation market | gastritis market | gaucher disease market | hemophilia b market | herpes simplex virus market | hiatal hernia market | holter monitor market | huntington's disease market | hyperkalemia market | hyperuricemia market | idiopathic pulmonary fibrosis market | idiopathic thrombocytopenic purpura market | invasive candidiasis market | ischemic stroke market | jak inhibitor market | langerhans cell histiocytosis market | leukocyte adhesion deficiency market | metastatic urothelial carcinoma market | microscopy device market | monoclonal gammopathy of undetermined significance market | mrna based vaccines and therapeutics market | multiple myeloma market | neovascular age-related macular degeneration market | nephropathic cystinosis market | nerve repair and regeneration devices- market insights | nonmuscle invasive bladder cancer market | oncolytic virus cancer therapy market | ophthalmic laser devices market

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com